The International Association for the Study of Lung Cancer (IASLC)
says the move by the U.S. Food and Drug Administration (FDA) to grant
accelerated approval for a cutting-edge lung cancer treatment is a
positive step forward that may help many patients improve their
survival.
In early October, the FDA granted accelerated approval for
pembrolizumab (Keytruda) to treat patients with advanced (metastatic)
non-small cell lung cancer (NSCLC) whose disease continued to progress
after other treatments, and with tumors that have a protein called
PD-L1.
No comments:
Post a Comment